治疗调节IL-6/STAT-3和氧化由纤维酸在性结肠炎患者:一个随机对照试点研究
Khlood Mohammad Aldossary1, Mahmoud S Abdallah2,3, Noha Kamal2
1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Pharmacotherapy
|December 2, 2025
概括
作为一种附加疗法,纤维酸显著降低了性结肠炎患者的炎症并改善了他们的生活质量. 这项研究强调了纤维酸.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 过氧体增殖器激活受体α (PPARα) 在免疫媒介肠道疾病中起着保护作用.
- PPARα 抑制了交白素-6 (IL-6) 诱导的信号传感器和转录因子3 (STAT3) 激活的激活器.
研究的目的:
- 为了评估费诺纤维酸与梅萨拉结合在性结肠炎 (UC) 患者的抗炎作用.
- 评估对IL-6/STAT3信号传递和氧化 (NO) 途径的影响.
- 为了确定疾病活动和生活质量的变化.
主要方法:
- 一项为期6个月的双盲随机对照试验,涉及60名轻度至中度UC患者.
- 患者接受了梅萨拉加安慰剂或梅萨拉加芬纤维酸 (160毫克/天).
- 测量了疾病活动指数 (DAI),简式-36 (SF-36),以及IL-6,STAT3,NO和C反应蛋白 (CRP) 的血清水平.
主要成果:
- 两组都显示了DAI,IL-6,STAT3,NO和CRP的减少,SF-36得分得到改善.
- 费诺纤维酸组在DAI,IL-6,STAT3,NO和CRP中表现出显著更大的减少.
- 与安慰剂相比, fenofibrate 组在 SF-36 评分上也显示出明显更大的改善.
结论:
- 费诺纤维酸证明了作为一种有效的补充疗法的潜力,用于轻度至中度UC.
- 纤维酸调节炎症通路,提高患者的生活质量.
- 需要进一步的研究来证实这些发现在更大的患者队列中.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
617
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
617
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
Atherosclerosis III: Management
296
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296


